BLA 761192 · Mediwound, LTD
Nexobrid
Anacaulase-Bcdb · Topical
NovelOrphanCDER novel approval, Dec 28, 2022: To remove eschar in adults with deep partial thickness or full thickness thermal burns
Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Dec 28, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 11, 2025.
NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns Burns on the face, perineum, or genitalia Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease Circumferential burns Burns in patients with significant cardiopulmonary disease, including inhalation injury NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance. Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal. NEXOBRID contains proteolytic enzymes and is indicated for eschar removal in adults and pediatric patients with deep partial thickness and/or full thickness thermal burns ( 1 ). Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns ( 1 ). Burns on the face, perineum, or genitalia ( 1 ). Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease ( 1 ). Circumferential burns ( 1 ). Burns in patients with significant cardiopulmonary disease, including inhalation injury ( 1 ). NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance ( 1 ) Treatment of burn wounds where medical devices...
Mechanism: The mixture of enzymes in NEXOBRID dissolves burn wound eschar. The specific components responsible for this effect have not been identified.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 15, 2024 Supplement 10 · Efficacy OrphanLabelLetter
- Dec 28, 2022 Original approval · Type 1 - New Molecular Entity NovelOrphanLetterLabelReview
1 products under this application
- NEXOBRID · ANACAULASE-BCDB 8.8% · GEL, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Anacaulase" as an intervention, any sponsor and status, largest first.
- A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)Pivotal-lookingRecruiting
MediWound LtdIndustry
NCT06568627 · 216 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 2026
Drug: EscharEx (EX-03); Placebo (Gel vehicle) · For: Venous Leg Ulcer (VLU)
Sites: Phoenix, Arizona; Fresno, California; Los Angeles, California · 60 sites in all
MediWound LtdIndustry
NCT06690177 · 45 participants (planned) · Start Jan 10, 2027 · Primary completion Nov 4, 2028
Drug: EscharEx (EX-03); Placebo (Gel vehicle) · For: Venus Leg Ulcers
Sites: Maimi, Florida; Warsaw, Poland
MediWound LtdIndustry
NCT07692178 · 20 participants (planned) · Start Aug 2026 · Primary completion Aug 2028
Drug: EX-03 · For: Venous Leg Ulcer (VLU)
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Early Enzymatic Burn Debridement: Results of the DETECT Multicenter Randomized Controlled Trial.
Shoham Y, Rosenberg L, Hickerson W, et al. · J Burn Care Res 2024 · Randomized Controlled Trial, Multicenter Study
- A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT.
Rosenberg L, Krieger Y, Bogdanov-Berezovski A, et al. · Burns 2014 · Multicenter Study, Randomized Controlled Trial
- Bromelain-based enzymatic burn debridement: A systematic review of clinical studies on patient safety, efficacy and long-term outcomes.
Shoham Y, Gasteratos K, Singer AJ, et al. · Int Wound J 2023 · Systematic Review
- Histopathological Changes Following Bromelain-Based Enzymatic Debridement (NexoBrid®): A Comprehensive Systematic Review of Preclinical and Clinical Evidence.
Avadanei-Luca S, Moraru DC, Bulgaru-Iliescu AI, et al. · Med Sci (Basel) 2026 · Systematic Review
- An Expanded Access Program With NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries in Adult and Pediatric Patients.
Kahn SA, Schulz J, Pham T, et al. · J Burn Care Res 2026 · Clinical Trial, Multicenter Study
- Open label randomized controlled trial of the efficacy and safety of NexoBrid compared to standard of care in children with burns.
Shoham Y, Rosenberg L, Narayan RP, et al. · Burns 2025 · Randomized Controlled Trial, Multicenter Study
Sponsor: Mediwound, LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.